Clonal Progenitor Cell Exosomes for Consistent Angiogenesis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The availability of reproducible, uniform exosomes for therapeutic, diagnostic, and research applications is limited due to the senescence of most cell sources, which restricts their replicative capacity and consistency.

Innovation Solution

The use of clonal progenitor cell lines, such as the 30-MV2-6 human clonal progenitor cell line, which have extended replicative capacity and uniform exosome production, allowing for consistent isolation and application of exosomes containing specific miRNAs and markers like CD63 and miR-126, enhancing vascular tube formation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If exosomes are isolated from conventional cell sources (adult stem cells, primary cells), then the exosomes can be obtained, but the replicative capacity is limited due to senescence and consistency is poor

Engineering Contradiction:

Improveconsistency of exosome productionVSAvoidreplicative capacity of cell source

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent changes the fundamental parameter of cell source from conventional senescent cells to clonal progenitor cells with extended replicative capacity. This parameter change enables continuous production of consistent exosomes without the senescence limitations of adult stem cells or primary cells, directly resolving the contradiction between reliability and duration of action.

Inventive Principle:

Principle #35Parameter changes

2Productivity

If clonal progenitor cell lines are used, then replicative capacity and consistency are extended, but the cell source becomes more specialized

Engineering Contradiction:

Improveabundance of exosomesVSAvoidapplicability to different therapeutic areas

Core Design Contradiction:

ProductivityVSAdaptability or versatility

Solution Approach 1:

The patent demonstrates that clonal progenitor cell lines can be differentiated into multiple cell types (cardiomyocytes, neurons, osteocytes, chondrocytes, hepatocytes, pancreatic beta cells), making the cell line universally applicable for generating exosomes for various therapeutic areas. This multi-functionality resolves the contradiction between productivity and adaptability.

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Manufacturing precision

If conventional cell sources are used, then the exosome isolation process is simpler, but the exosome composition varies and reproducibility is limited

Engineering Contradiction:

Improveuniformity of exosome compositionVSAvoidcomplexity of cell culture system

Core Design Contradiction:

Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent employs clonal progenitor cell lines that maintain genetic homogeneity and consistent differentiation potential, resulting in uniform exosome composition. The controlled differentiation protocol ensures reproducible exosome characteristics across batches, directly addressing the manufacturing precision requirement while managing system complexity through standardized protocols.

Inventive Principle:

Principle #33Homogeneity

Data Source

PatentUS11274281B2Exosomes from clonal progenitor cells

Publication Date: 2022.03.15 RECYTE THERAPEUTICS

AI summary

The invention provides methods, compositions, uses and kits relating to exosomes isolated from progenitor cells.